Related references
Note: Only part of the references are listed.Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
Anna Buder et al.
BIOMOLECULES (2021)
Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Response
Sheng-Fang Su et al.
JCO PRECISION ONCOLOGY (2021)
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro et al.
NATURE CANCER (2021)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
U1 snRNP regulates cancer cell migration and invasion in vitro
Jung-Min Oh et al.
NATURE COMMUNICATIONS (2020)
Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability
Wa Zhang et al.
CANCERS (2020)
g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)
Uku Raudvere et al.
NUCLEIC ACIDS RESEARCH (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Isabelle Solassol et al.
BIOMOLECULES (2019)
Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients
Le Son Tran et al.
PLOS ONE (2019)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Alicia Hulbert et al.
CLINICAL CANCER RESEARCH (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis
Chenzi Zhang et al.
JOURNAL OF CANCER (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment
Xiaomin Niu et al.
CLINICAL CANCER RESEARCH (2017)
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Shigenari Nukaga et al.
CANCER RESEARCH (2017)
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
Ronglai Shen et al.
NUCLEIC ACIDS RESEARCH (2016)
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Jun Wang et al.
ONCOTARGETS AND THERAPY (2016)
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
Ying Jin et al.
ONCOTARGET (2016)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines
Masashi Maeda et al.
LUNG CANCER (2015)
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution
Aaron M. Newman et al.
BIOINFORMATICS (2014)
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly
Ilari Scheinin et al.
GENOME RESEARCH (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Methy-Pipe: An Integrated Bioinformatics Pipeline for Whole Genome Bisulfite Sequencing Data Analysis
Peiyong Jiang et al.
PLOS ONE (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients
Chong-Kin Liam et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Hideki Terai et al.
MOLECULAR CANCER RESEARCH (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Fulcrum: condensing redundant reads from high-throughput sequencing studies
Matthew S. Burriesci et al.
BIOINFORMATICS (2012)
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
Jueng Soo You et al.
CANCER CELL (2012)
Is There a Link Between Genome-Wide Hypomethylation in Blood and Cancer Risk?
Kevin Brennan et al.
CANCER PREVENTION RESEARCH (2012)
Epigenetic Mechanisms in Commonly Occurring Cancers
Lauren P. Blair et al.
DNA AND CELL BIOLOGY (2012)
Key epigenetic changes associated with lung cancer development
Heather H. Nelson et al.
EPIGENETICS (2012)
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
Suhaida A. Selamat et al.
GENOME RESEARCH (2012)
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
Makoto Maemondo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications
Felix Krueger et al.
BIOINFORMATICS (2011)
Genetic and epigenetic changes in lung carcinoma and their clinical implications
Jing Wen et al.
MODERN PATHOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
Takafumi Kubo et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Small cell lung cancer
Taimur Sher et al.
MAYO CLINIC PROCEEDINGS (2008)
DNA methylation profile of 28 potential marker loci in malignant mesothelioma
Jeffrey A. Tsou et al.
LUNG CANCER (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Epigenetics as a mechanism driving polygenic clinical drug resistance
RM Glasspool et al.
BRITISH JOURNAL OF CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
